Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma is a topic covered in the Evidence-Based Medicine Guidelines.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma ID - 451501 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/451501/all/Long_acting_beta2_agonists_versus_anti_leukotrienes_as_add_on_therapy_to_inhaled_corticosteroids_for_chronic_asthma PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -